CNCE
Income statement / Annual
Last year (2021), Concert Pharmaceuticals, Inc.'s total revenue was $32.58 M,
an increase of 312.28% from the previous year.
In 2021, Concert Pharmaceuticals, Inc.'s net income was -$82.59 M.
See Concert Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$32.58 M |
$7.90 M |
$1.08 M |
$10.51 M |
$143.89 M |
$174,000.00 |
$66.73 M |
$8.58 M |
$25.41 M |
$12.85 M |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$32.58 M
|
$7.90 M
|
$1.08 M
|
$10.51 M
|
$143.89 M
|
$174,000.00
|
$66.73 M
|
$8.58 M
|
$25.41 M
|
$12.85 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$87.56 M
|
$61.62 M
|
$59.82 M
|
$43.15 M
|
$30.22 M
|
$36.98 M
|
$28.89 M
|
$27.47 M
|
$21.79 M
|
$24.19 M
|
| General & Administrative Expenses |
$22.25 M
|
$18.62 M
|
$19.97 M
|
$22.94 M
|
$21.02 M
|
$14.36 M
|
$13.06 M
|
$11.70 M
|
$8.03 M
|
$7.27 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.25 M
|
$18.62 M
|
$19.97 M
|
$22.94 M
|
$21.02 M
|
$14.36 M
|
$13.06 M
|
$11.70 M
|
$8.03 M
|
$7.27 M
|
| Other Expenses |
$283,000.00
|
$301,000.00
|
$306,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20.90 M
|
$12.84 M
|
$0.00
|
| Operating Expenses |
$110.09 M
|
$80.55 M
|
$80.09 M
|
$66.09 M
|
$51.24 M
|
$51.34 M
|
$41.94 M
|
$39.17 M
|
$29.82 M
|
$31.46 M
|
| Cost And Expenses |
$110.09 M
|
$80.55 M
|
$80.09 M
|
$66.09 M
|
$51.24 M
|
$51.34 M
|
$41.94 M
|
$39.17 M
|
$29.82 M
|
$31.46 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
-$127,000.00
|
$815,000.00
|
$447,000.00
|
$309,000.00
|
$1.15 M
|
$1.67 M
|
$1.86 M
|
| Depreciation & Amortization |
$4.02 M
|
$3.81 M
|
$827,000.00
|
$1.25 M
|
$1.01 M
|
$893,000.00
|
$785,000.00
|
$1.05 M
|
$1.35 M
|
$1.45 M
|
| EBITDA |
-$73.49 M |
-$68.84 M |
-$78.19 M |
-$54.46 M |
$97.16 M |
-$49.83 M |
$25.70 M |
-$29.50 M |
-$3.04 M |
-$17.14 M |
| EBITDA Ratio |
-2.26
|
-8.71
|
-72.6
|
-5.18
|
0.68
|
-286.36
|
0.39
|
-3.44
|
-0.12
|
-1.33
|
| Operating Income Ratio |
-2.38
|
-9.19
|
-73.37
|
-5.29
|
0.64
|
-294.06
|
0.37
|
-3.57
|
-0.17
|
-1.45
|
| Total Other Income/Expenses Net |
-$2.54 M
|
-$2.20 M
|
$849,000.00
|
-$127,000.00
|
$2.69 M
|
$447,000.00
|
-$185,000.00
|
-$1.10 M
|
-$1.65 M
|
-$1.83 M
|
| Income Before Tax |
-$80.05 M
|
-$74.85 M
|
-$78.17 M
|
-$55.71 M
|
$95.34 M
|
-$50.72 M
|
$24.60 M
|
-$31.70 M
|
-$6.06 M
|
-$20.44 M
|
| Income Before Tax Ratio |
-2.46
|
-9.47
|
-72.58
|
-5.3
|
0.66
|
-291.49
|
0.37
|
-3.7
|
-0.24
|
-1.59
|
| Income Tax Expense |
$2.54 M
|
-$85,000.00
|
-$837,000.00
|
$313,000.00
|
-$300,000.00
|
$447,000.00
|
$429,000.00
|
$49,000.00
|
$21,000.00
|
$22,000.00
|
| Net Income |
-$82.59 M
|
-$74.77 M
|
-$77.33 M
|
-$56.02 M
|
$95.64 M
|
-$50.72 M
|
$24.17 M
|
-$31.70 M
|
-$6.06 M
|
-$20.44 M
|
| Net Income Ratio |
-2.54
|
-9.46
|
-71.8
|
-5.33
|
0.66
|
-291.49
|
0.36
|
-3.7
|
-0.24
|
-1.59
|
| EPS |
-2.4 |
-2.4 |
-3.26 |
-2.4 |
4.22 |
-2.28 |
1.14 |
-2 |
-0.35 |
-1.82 |
| EPS Diluted |
-2.4 |
-2.4 |
-3.26 |
-2.4 |
4.08 |
-2.28 |
1.09 |
-2 |
-0.35 |
-1.82 |
| Weighted Average Shares Out |
$34.41 M
|
$31.20 M
|
$23.74 M
|
$23.37 M
|
$22.64 M
|
$22.23 M
|
$21.15 M
|
$15.84 M
|
$17.22 M
|
$11.21 M
|
| Weighted Average Shares Out Diluted |
$34.41 M
|
$31.20 M
|
$23.74 M
|
$23.37 M
|
$23.44 M
|
$22.23 M
|
$22.27 M
|
$15.84 M
|
$17.22 M
|
$11.21 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
